Sanofi and Regeneron deepen alliance with $1 billion upfront for new antibody program
Sanofi will pay Regeneron $1 billion up front and up to $7 billion in milestones as the two firms expand their collaboration on next-generation immunology antibodies.
The French drugmaker Sanofi and U.S. biotech Regeneron Pharmaceuticals have renewed their partnership that produced Dupixent, adding a new joint effort to develop antibody therapies for immune-related diseases. Sanofi will provide an initial $1 billion payment, with the possibility of receiving up to $7 billion in future milestone payments. Regeneron will lead the research and development work, while Sanofi will handle worldwide commercialization, and any profits will be shared equally. The companies highlighted their complementary strengths in scientific discovery and global market reach.
Why it matters
The deal could accelerate the creation of new immune-system drugs and shape the competitive landscape of biotech and pharma markets.
In this story
